Relmada Therapeutics Inc (RLMD)

NASDAQ
23.82
+0.20(+0.85%)
After Hours
23.82
-0.09(-0.38%)
- Real-time Data
  • Volume:
    35,814
  • Bid/Ask:
    23.03/25.43
  • Day's Range:
    23.09 - 23.91

RLMD Overview

Prev. Close
23.62
Day's Range
23.09-23.91
Revenue
-
Open
23.74
52 wk Range
20.6-40
EPS
-5.23
Volume
35,814
Market Cap
416.21M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
218,875
P/E Ratio
-
Beta
0.11
1-Year Change
-28.55%
Shares Outstanding
17,472,986
Next Earnings Date
Nov 15, 2021
What is your sentiment on Relmada Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Relmada Therapeutics Inc News

Relmada Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell

Relmada Therapeutics Inc Company Profile

Relmada Therapeutics Inc Company Profile

Employees
14

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.